This question tests antidote selection for acetaminophen overdose in a patient with risk factors. The patient ingested 20 g of acetaminophen with a toxic level (210 mcg/mL at 6 hours) above the treatment line on the Rumack-Matthew nomogram, with alcohol use disorder as an additional risk factor. N-acetylcysteine (A) is the specific antidote that replenishes glutathione stores depleted by toxic acetaminophen metabolites, preventing hepatotoxicity when given within 8-10 hours of ingestion. Naloxone (B) reverses opioid effects, not acetaminophen toxicity. Atropine (C) treats cholinergic toxicity or symptomatic bradycardia. Flumazenil (D) reverses benzodiazepine effects. The IV N-acetylcysteine protocol includes a loading dose (150 mg/kg over 1 hour), followed by maintenance infusions (50 mg/kg over 4 hours, then 100 mg/kg over 16 hours). Daily alcohol use increases susceptibility to acetaminophen hepatotoxicity through glutathione depletion and CYP2E1 induction.

This question tests antidote selection for sulfonylurea-induced hypoglycemia. The patient has critically low glucose (38 mg/dL) after taking extra glipizide, presenting with confusion and vomiting typical of severe hypoglycemia. Octreotide (A) is the correct antidote as it inhibits insulin secretion from pancreatic beta cells, counteracting sulfonylurea's mechanism and preventing recurrent hypoglycemia that often occurs with dextrose alone. Protamine sulfate (B) reverses heparin anticoagulation, not hypoglycemia. Vitamin K (C) reverses warfarin anticoagulation, which is unrelated to this case. Leucovorin (D) provides folate rescue for methotrexate toxicity, not sulfonylurea overdose. For sulfonylurea overdose, octreotide prevents the hyperinsulinemic response to dextrose administration, reducing the risk of rebound hypoglycemia. The typical dose is 50-100 micrograms subcutaneously every 6-12 hours, with concurrent dextrose support and frequent glucose monitoring.

This question tests recognition and treatment of opioid overdose with classic toxidrome. The patient presents with the opioid triad: respiratory depression (RR 6/min), decreased consciousness, and pinpoint pupils, with positive urine toxicology for opioids. Naloxone 0.04-0.4 mg IV (A) is the specific opioid antagonist that competitively reverses respiratory depression, with dosing titrated to restore adequate ventilation without precipitating withdrawal. Naltrexone (B) is an oral long-acting opioid antagonist used for addiction treatment, not acute reversal. Fomepizole (C) treats toxic alcohol ingestions. Physostigmine (D) reverses anticholinergic toxicity, which presents with mydriasis, not miosis. Start with lower naloxone doses (0.04-0.1 mg) and titrate to avoid precipitating severe withdrawal in opioid-dependent patients. The goal is adequate ventilation (RR >12), not full alertness, and repeated doses may be needed due to naloxone's shorter half-life compared to many opioids.

This question tests recognition of severe statin-induced rhabdomyolysis from drug interaction. The patient developed severe myalgias and dark urine after starting clarithromycin while on high-dose simvastatin, with markedly elevated CK (18,500 U/L) and acute kidney injury. Dark urine with severe myalgias suggesting rhabdomyolysis (B) indicates severe toxicity, as myoglobin release causes the characteristic dark urine and can lead to acute tubular necrosis. Mild headache (A) is a minor symptom not indicating severe toxicity. Intermittent sneezing (C) is unrelated to statin toxicity. Transient nausea (D) without dehydration is also not indicative of severe toxicity. Clarithromycin is a strong CYP3A4 inhibitor that dramatically increases simvastatin levels, with risk highest at the 80 mg dose. Management includes immediate discontinuation of both drugs, aggressive IV hydration, and monitoring for complications including hyperkalemia and acute kidney injury.

This question tests initial management of cocaine toxicity, prioritizing sympatholysis. The key patient-specific factor is the severe hypertension, tachycardia, and chest pain from catecholamine surge. Benzodiazepines are best to reduce sympathetic outflow, agitation, and cardiovascular stress safely. Propranolol monotherapy risks unopposed alpha stimulation; flumazenil irrelevant; N-acetylcysteine not indicated. A pearl is to avoid beta-blockers in cocaine use due to potential coronary vasospasm worsening. Nitroglycerin or phentolamine can be added for refractory hypertension.

This question tests immediate management of calcium channel blocker overdose in a pediatric patient. The 2-year-old presents with hypotension (86/48 mmHg), tachycardia, and hypoglycemia after ingesting extended-release nifedipine within 30 minutes. Activated charcoal (A) is the most important initial action because it can prevent further absorption of the sustained-release formulation if given within 1-2 hours of ingestion, especially critical with extended-release preparations that continue releasing drug. N-acetylcysteine (B) treats acetaminophen overdose, not calcium channel blockers. Atropine (C) is for cholinergic toxicity with bradycardia and excessive secretions, which this patient doesn't exhibit. Naloxone (D) reverses opioid effects, not calcium channel blocker toxicity. For calcium channel blocker overdoses, remember the treatment triad: decontamination (activated charcoal), calcium supplementation, and vasopressor support. Extended-release formulations pose particular danger due to prolonged absorption and delayed peak effects.

This question tests initial management of methylene chloride exposure with carbon monoxide formation. The patient has elevated carboxyhemoglobin (18%) from methylene chloride metabolism to carbon monoxide, presenting with headache and dizziness after paint stripper inhalation. Administering 100% oxygen via nonrebreather mask and removing from exposure (A) is the most important initial action, as high-flow oxygen accelerates carbon monoxide elimination and prevents further exposure. Flumazenil (B) is inappropriate as this is an inhalation exposure producing carbon monoxide, not sedative overdose. Activated charcoal (C) doesn't bind inhaled toxins and is useless for gas exposures. Deferoxamine (D) chelates iron, not carbon monoxide. Methylene chloride uniquely continues producing carbon monoxide through hepatic metabolism even after exposure ends, potentially causing delayed or prolonged toxicity. Monitor carboxyhemoglobin levels serially and consider hyperbaric oxygen for severe poisoning, especially with the patient's cardiac history.

This question tests appropriate monitoring parameters for salicylate toxicity. The patient presents with classic salicylate toxicity symptoms: tinnitus, hyperventilation (RR 30/min), and mixed respiratory alkalosis with metabolic acidosis (pH 7.48, low bicarbonate, low PCO2). Serial serum salicylate concentrations and acid-base status (B) are essential for monitoring salicylate toxicity because levels can continue to rise, and acid-base disturbances guide treatment decisions including alkalinization and hemodialysis. Acetaminophen concentration at 4 hours (A) is irrelevant as the patient took aspirin, not acetaminophen. INR monitoring (C) would be appropriate for warfarin overdose, not salicylate toxicity. Serum digoxin concentration (D) is unnecessary without digoxin exposure. In salicylate toxicity, monitor levels every 2-4 hours until declining, along with frequent acid-base assessment, as tissue distribution increases with acidemia. Remember that clinical severity doesn't always correlate with serum levels, especially in chronic toxicity.

This question tests the appropriate antidote selection for benzodiazepine overdose with concurrent alcohol intoxication. The patient presents with severe drowsiness, respiratory depression (RR 8/min, O2 sat 90%), and positive urine toxicology for benzodiazepines after alprazolam overdose with alcohol. Flumazenil (B) is the specific benzodiazepine receptor antagonist that competitively reverses benzodiazepine effects, making it the correct choice for this patient with respiratory depression. Naloxone (A) is incorrect as it reverses opioid effects, not benzodiazepines, and the patient has no evidence of opioid exposure. N-acetylcysteine (C) is the antidote for acetaminophen overdose, and fomepizole (D) treats toxic alcohol ingestions, neither of which apply here. When using flumazenil, monitor for seizures, especially in chronic benzodiazepine users or those with seizure history, and be aware that its shorter half-life compared to most benzodiazepines may require repeated dosing.

This question tests recognition of severe bupropion toxicity, focusing on neurologic and cardiac effects. The key patient-specific factor is the large ingestion of extended-release bupropion with prolonged QTc indicating high risk. Seizures and cardiac dysrhythmias indicate severe toxicity due to sodium channel blockade and lowered seizure threshold. Mild headache is common but not severe; increased appetite atypical; runny nose irrelevant. A pearl is that seizures can be delayed up to 24 hours with XL formulations. Treat wide QRS with sodium bicarbonate and use benzodiazepines for seizure prophylaxis.